Trientine hydrochloride is the USAN for trientine dihydrochloride.
Administer trientine formulations at least 1 hour apart from any other oral drug.
Worsening of clinical symptoms, including neurological deterioration, may occur at the beginning of trientine therapy due to mobilization of excess stores of copper. Adjust the dosage or discontinue trientine if the patient’s clinical condition worsens.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Cufence (Univar Solutions); Cuprior (Orphalan); Cuvrior (Orphalan); Syprine (Bausch Health US)
- INDICATIONS: Wilson’s disease
- SYNONYM: triethylenetetramine
- CLASS: Chelator
- HALF-LIFE: 13.8 to 16.5 hours (trientine tetrahydrochloride)
- FDA APPROVAL DATE: 08/11/1985 (trientine dihydrochloride); 04/28/2022 (trientine tetrahydrochloride)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Ferrous Sulfate, mineral supplements (e.g. iron, zinc, calcium, or magnesium) - PREGNANCY: Chelator-induced copper deficiency may have adverse effects on the fetus.
Please login to view the rest of this drug profile.
Page last updated 04/15/2024
